Future of personalized cancer care is promising and near

April 19, 2011, University of Alabama at Birmingham

Cancer survival rates could improve soon with whole-genome sequencing, according to two studies published in the April 20, 2011, issue of the Journal of the American Medical Association that describe the first clinical applications of the high-tech process in patients with cancer.

The papers are remarkable examples of the power that genomic data hold for patients with a cancer diagnosis, according to an accompanying editorial by Boris Pasche, M.D., deputy director of the University of Alabama at Birmingham Comprehensive Cancer Center and professor of medicine, and Devin Absher, Ph.D., of the HudsonAlpha Institute for Biotechnology.

Whole-genome sequencing is a high-tech process that essentially maps a person's DNA and analyzes it for mutations. This has enabled cancer therapies to evolve from a standard therapy for all patients with a given type of cancer to a slightly more personalized treatment.

"In patients with , and gastric cancer, we now have specific approaches for tumors that exhibit certain genetic abnormalities," Pasche says.

"Whole-genome sequencing gives us the ability to screen a much larger number of tumors and correlate them with the outcome of the patient, so it is very likely that our targeted therapy is going to be exploding in the next decade," Pasche says.

Half of all men and one-third of all women in the United States will develop cancer during their lifetimes, according to the American Cancer Society; and few, if any, do not know someone who has had cancer or died because of it. This new advance could change that.

"In one study, a patient with leukemia had a poor prognosis, but through sequencing, this patient was found to have a gene that showed they would react favorably with a different therapy than originally recommended," Pasche says. "If patients have certain genes, they may not respond to certain treatments. But whole-genome sequencing gives a full picture of the genetic make-up of the tumor and the patient, and it may allow the physician to target a new treatment."

Pasche says the unbiased picture of the sequenced DNA enables physicians to look at tumors in a way not possible previously. Even when the technology finally was available, it was too expensive. Now, the cost to sequence a patient's entire genome and the genome of their tumor is down by more than 100 fold, but still ranges from $30,000 to $40,000.

"Prices are still dropping very rapidly; in the next 10 years, it will cost less than $10,000, and it certainly will be more affordable in the next five years," says Pasche, who believes having sequencing covered by insurance or otherwise is a work in progress.

At UAB, Pasche says whole-genome sequencing is being used in many projects, most notably in a clinical trial for women with triple-negative breast cancer.

"There is a high degree of expectation with whole-genome sequencing," he says. "The hope is that it will help survival rates of those with cancer."

Related Stories

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.